5DiMasi JA.The value of improving the productivity of the drug development process:faster times and better decisions[J].Pharmacoeconomics,2002,20(13):1-10.
6Clemens K,Garrison LP,Jones A,et al.Strategic use of pharmacoeconomic research in early drug development and global pricing[J].Pharmacoeconomics,1993,4(5):315-322.
7Annemans L,Geneste B,Jolain B.Early modelling for assessing health and economic outcomes of drug therapy[J].Value in Health,2000,3(6):427-434.
8Jones RN,Rubino CM,Bhavnani SM,et al.Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of Gatifloxacin and Levofloxacin against Streptococcus pneumoniae:report from the antimicrobial resistance rate epidemiology study team[J].Antimicrob Agents Chemother,2003,47(1):292-296.
9Sheiner LB.Learning versus confirming in clinical drug development[J].Clin Pharmacol Ther,1997(61):275-291.
10Hughes DA,Walley T.Economic evaluations during early(phase Ⅱ)drug development:a role for clinical trial simulations?[J].Pharmacoeconomics,2001,19(11):1 069-1 077.
